Identification of Multi-Target Mitochondrial, Cytoskeletal, and Proteostatic Inhibitors for Frontotemporal Dementia via Single-Cell RNA Sequencing and Computational Drug Repurposing

Read full text Summarise with VIRAT
Authors: Glen Charles Ritschel, Claude
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Provisional patent specification filed with the United States Patent and Trademark Office (USPTO) by Glen Charles Ritschel, Ritschel Research, Tega Cay, South Carolina (Micro-Entity; filed March 2026). This specification discloses a computational drug repurposing method applied to single-cell RNA sequencing data from Frontotemporal Dementia patient frontal cortex tissue (GSE213733; Mccreary et al., 2022; 19,740 cells; 7 clusters). Differential expression analysis of the reactive astrocyte cluster (cluster 5) identified 3,567 FTD-dysregulated genes, from which 126 ChEMBL-tractable targets were extracted spanning mitochondrial complex subunits (NDUFA1, NDUFB1, COX4I1, MT-ND1, MT-ND4), cytoskeletal and axonal transport proteins (CFL1, VIM, DPYSL2, DPYSL3, MAP1B, STMN1), proteostatic factors (UBB, UBC, NEDD8, POMP), and neuroprotective proteins (CLU, PARK7, VGF, GAP43). Screening of 6,251 unique compounds with USPTO prior art verification identified all 6,251 as NOVEL_ALL (100%). Top leads: CHEMBL5653589 (73 targets, score 739.2 — the highest composite score in the Ritschel Research portfolio across 29 patents), CHEMBL3752910 (50 targets, score 508.8), MOLIBRESIB (CHEMBL1232461, BET bromodomain inhibitor, 13 targets, score 137.5). Critical pan-neurodegeneration signal: CHEMBL5653589 ranks first and MOLIBRESIB ranks second or third independently across FTD (this patent), ALS (Patent 27, GSE153960), and Huntington's Disease (Patent 28, GSE165030) — three anatomically distinct neurodegenerative conditions from independent transcriptomic analyses. Pipeline code: https://github.com/glenritschel/ftd-scrna

Fields of Study & Subjects

Computational Drug Discovery Methods Alzheimer's disease research and treatments Cholinesterase and Neurodegenerative Diseases

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
26 March 2026
Language
EN